Using these original methods to identify tumour PI3K/AKT/PTEN pathway status, a secondary endpoint subgroup analysis suggested that the addition of capivasertib to fulvestrant conferred benefit for participants with either PI3K/AKT/PTEN pathway-altered advanced breast cancer or pathway non-altered advanced breast cancer (referred herein as the original pathway-altered and original pathway non-altered subgroups).17 This evidence concerns the gene PTEN and breast cancer.